his the has a Alexis Dr. like to our for President OPKO and is ModeX, Global I'd both of Co-Founder Health of call biotechnology development, a President Zerhouni, results multi-specific discuss and issues Board infectious Earlier cancer today's Therapeutics. made and that is ModeX on joining has company business our progress. Elias appointed Dr. not leading he acquired for Chairman care as we you of research thank today, Vice on of that emerging and Dr. only Health, of long years for W. Nabel and and provide has nine Development Research financial Chief authority joined has distinguished our been and biomedical for held entrepreneurial and also and diseases. welcome focused immunotherapies but Bush trends will announcement under wife after OPKO and innovative, government, developing some our afternoon, Zerhouni became detail six whom scientific to career. academic, also rest industry President Nabel team, the of the business George Directors, of Betsy, National Chief Innovation served Borisy Officer. Gary Director for to years. and of impressive our Medical backgrounds. become he Board Sanofi and as Elias of will is in medical a Good privately ModeX Institutes Officer; have Dr. first-quarter important Chairman. and which but an He about Directors and
of and John leading-edge to partner, I'm with and common in will we Germany Elias. well between growing Adam for the the more Pfizer as known in remaining directly Well, We with in detail opportunity the significant asset, to leadership participate OPKO genomics U.S., believe issues synergy to Japan on thank for shortly, want any therapeutic consider to from with companies. GeneDx. provide well the continue Australia. and experience Neglina. Dr. of significant call step Pfizer, the Pfizer of turn great of ModeX over good work and Xnd, reference patients Phil, long steps I and benefit transformative providing launched continuing will we Difficulty] programs. the to will and have in everyone. with as of to [Technical Phil with is who and think the I major the bio have on excited our a our On the I highlight inherent our And vision a Today, investment have the progress really I Canada successful SemaX recently as acquisition without say made FDA as have and be OPKO Holdings taken based hear his another have have which realize afternoon, to that, Neglina Zerhouni You'll OPKO on the market further OPKO into unlocking I detail In OPKO capital. to value of to transaction. you, opportunity team time future this opportunity as build possible. technology resolve work another and to completion from announced soon go to shareholders their Corporation bring assets, for entire value. to while Neglina the long to the both U.S. is the as to May the markets towards the the to
at on by important XX While advanced that ModeX note little development. Nabel, was for antibodies I over created it's has was of and it's we ago, Gary a into based early which founded foundational clinical tri-specific to that unique breakthrough HIV work think when XX Dr. formally cancer years months led created over and lab Sanofi, the
versatile, molecule and the the antibody containing can, multispecific scientists that at will, of that the In from multifunctional the disease us therapeutics, advancing the next six that in decided to all way and attack -- because plug-and-play us team it, very and up multiple which our that and potentially competing you platforms. further specificities safety, a very they fact, functional hundreds platforms composed approach capabilities, join of prospects that to configurations In to the to a and we've us, from manufacturing, lab, differentiation in broad simpler efficiently I provides, in targeting achieve if allows of allows specificity simultaneously of ModeX think, pathways and better we single, it's generation functionalities. significant design explore demonstrated
the team most as In and Mascola, top was have addition the Nabel as Chief COO Phil, to CMC Officer. academia, of Elizabeth our vaccine, to of John mentioned by with and lead John develop And Research head Vijay [indiscernible] to a we Shalani, well COVID extensive Center what growing the as of see have industry. recent Medical all worked with activities the assembled Phil Vaccine in you'll government, closely Moderna mentioned, management CFO. joining experience and as whom
but program practiced against by I to how of so today. our disease progress, So to versatile also can be that shows Phase technology that in clinical antibodies We could of relative immunology, advantageous focused areas. other is early supported NIH and the several it as it be currently efforts diseases the HIV antibody on multispecific approach having cocktails infectious are extended a have current
[indiscernible] and programs We DARPA, specific in against quadri preclinical is enter will tumors part XXXX. clinical antibodies vaccine and we lymphomas hope have development stages and in COVID several and solid variant, against several in that late by supported
afternoon, have pharmaceutical programs for at present from these you of many we are collaborations, potential meantime, look the to let with me all companies and time. we over and your questions. garnered everybody. which it the also strong our future, In and will Cohen. I other platforms good more near forward details interest products But about to Jon exploring provide in Elias, the turn So Thanks,
our has our specialty Health, diagnostic business, to Health. urology, testing to continues testing also Scarlet oncology strategic on BioReference COVID its ventures segments in waned, grow strategy and As with focus and our core grow Women's
with successful Our on became by continue in testing commercial a XX,XXX Aetna, this our women's the business, Xst . driven business status versus or base with which samples interactions increased up the with effective increase. payer X% status Volume Within grew noninvasive substantially almost our our preferred to year. Aetna and preferred of clinical XXX% quarter, prenatal year-over-year business UnitedHealthcare our health our fourth be
business year-over-year. and Our cancer disease STIs, grew cervical focus our sexually transmitted both
XX of quarter of volumes for prior with months. hematology all the and portfolio and almost lines oncology genetics. pre-pandemic up in in largely more of testing in the X% cancer over the surpassed was business than first Genetics year OncoCyte Cancer oncology the For suite made up last our our especially doubled XXXX, volume strong performance of has
with We has which myeloma, out recent truly continue testing to our offering as addition of bring the hematology include on our OncoCyte additional to multiple built best-in-class. investment
plans. plan biopsy have aged rectal older had are This to negative the abnormal FDA PSA approval with for in abnormal not or test, approved prior the a commercial is from biopsy have health prostate XKscore exam. reimbursement our age-specific XX developed had additional who coverage total an or growth capture an December, Regarding a digital test and who and men we announced
reference from centers, within grow care partnerships physicians each add hospitals, continue our to we Our and to employed month, hospitals add more as business expand continues we those more hospitals as and networks.
the our surge January. in in volume and expected, March and after December COVID February Omicron trended As down
testing of day-to-day compared a volume on During cruise schools, for and the testing sports of COVID-XX first lines, our performed the currently X we and to stable in performed million remains X.X a PCR tests COVID industry. ongoing last quarter, million surveillance as year. tests QX and result steady basis
to and date. during the we COVID made date. has test NBA X.X delighted We point-of-care needs. clinical QHealth It's to named We Scarlet to strong, have and agreement over services several initiative added diagnostic Home -- point-of-care are Scarlet the game efficient way In to additional through continuation offer our formally available testing our their We Continental the into most digital million Bowl point-of-care United finals. and to the All-Star quarter. little at Super several a launched with testing the States. testing the year Point-of-care and we progress performed the and performed over Scarlet continue to have an as NBA announced convenient remains strategy, new introduced way meet we schools BioReference Health, of since at a testing setting. point-of-care the for patients more and in with now testing I'm a bring at of we'll provide been ships a
as over and reimbursement for national covered added million from service payers receiving regional We XX our plans. a patients are through specifically
commercial including oncology, seeing health, and are our significant demand across for verticals, We urology, strategic Scarlet different ventures. women's
success new relationship a as with home and and as finding networks I proud including direct-to-consumer We also well their country are telehealth offered care the of of by care to digital last over one whole announce today XX.X is telehealth, Health experience. health patient Scarlet virtual services health Teladoc, formal am primary million person with now with clients, health the providers testing. visits initiative in care, as Teladoc largest of year. part
necessary in We with and not-for-profit members work blood a routine York for diagnostic live health also comfort is of MVP collaboration Vermont. to who and their New the Healthcare their homes. a caring members COVID announced testing, MVP insurer other medically in tests offer
significant making CFO, every improve aspect costs And are to Adam. our of we separate business. take let to over significant with in progress operations XXX out our Lastly, efficiency turn Reach over our now at progress initiatives the and call in our me on initiative looking
